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homologous series of [18F]-labeled
dopamine D2/3 receptor agonists based on
the 2-aminomethylchroman scaffold as
potential PET tracers
Vladimir Shalgunov1, Jan-Peter van Wieringen2, Henk M. Janssen3, P. Michel Fransen3, Rudi A.J.O. Dierckx1,
Martin C. Michel4, Jan Booij2 and Philip H. Elsinga1*Abstract
Background: Agonist positron emission tomography (PET) tracers for dopamine D2/3 receptors (D2/3Rs) offer greater
sensitivity to changes in endogenous dopamine levels than D2/3R antagonist tracers. D2/3R agonist tracers currently
available for clinical research are labeled with the short-lived isotope carbon-11, which limits their use. We aimed to
develop high-affinity D2R agonists amenable for labeling with the longer-living fluorine-18. Here, we report the evaluation
as potential PET tracers of two homologous series of [18F]fluorinated tracers based on the 2-aminomethylchroman-7-ol
(AMC) scaffold: (R)-2-((4-(2-fluoroalkoxy)benzylamino)methyl)chroman-7-ols (AMC13 homologues) and (R)-2-((2-(4-
(4-(fluoroalkoxy)phenyl)piperazin-1-yl)ethylamino)methyl)chroman-7-ols (AMC15 homologues). We varied the length of
the 18F-fluoroalkyl chain in these structures to balance brain penetration and non-specific binding of the radioligands
by adjusting their lipophilicity.
Methods: The tracers were evaluated in brain slices of Sprague-Dawley rats by in vitro autoradiography and in living
rats by microPET imaging and ex vivo autoradiography. PET data were analyzed with one- and two-tissue
compartmental models (1TCM/2TCM), simplified reference tissue model (SRTM), and Logan graphical analysis.
Specificity of binding was tested by blocking D2/3R with raclopride.
Results: Homologues with a shorter fluoroalkyl chain consistently showed greater D2/3R-specific-to-total binding ratios
in the striatum than those with longer chains. The fluoroethoxy homologue of AMC13 ([18F]FEt-AMC13) demonstrated
the highest degree of D2/3R-specific binding among the evaluated tracers: mean striatum-to-cerebellum uptake ratio
reached 4.4 in vitro and 2.1/2.8 in vivo/ex vivo (PET/autoradiography). Striatal binding potential (BPND) relative to
cerebellum was 0.51–0.63 depending on the estimation method. Radiometabolites of [18F]FEt-AMC13 did not
enter the brain. In vitro, application of 10 μmol/L raclopride reduced D2/3R-specific binding of [18F]FEt-AMC13 in
the striatum by 81 %. In vivo, pre-treatment with 1 mg/kg (2.9 μmol/kg) raclopride led to 17–39 % decrease in
D2/3R-specific binding in the striatum.
Conclusions: Varying the length of the [18F]fluoroalkyl chain helped improve the characteristics of the original
candidate tracers. Further modifications of the current lead [18F]FEt-AMC13 can provide an agonist radiopharmaceutical
suitable for D2/3R imaging by PET.
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Fig. 1 Structures of the evaluated homologues of AMC-13
and AMC-15
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Dysregulation of dopamine signaling through dopamine
D2 and D3 receptors (D2/3Rs) is implicated in many neuro-
psychiatric disorders [1–4], making imaging of D2/3Rs by
positron emission tomography (PET) highly relevant.
Majority of PET tracers developed for D2/3R imaging
are antagonists [5], but in the last two decades, agonists
have attracted attention as potential PET ligands for G
protein-coupled neurotransmitter receptors (GPCRs). In
in vitro competition studies, agonists consistently show
higher affinity for receptor molecules bound to G proteins
(“high-affinity state”) than for free receptors (“low-affinity
state”) [6–8]. Agonists are therefore expected to selectively
recognize the “high-affinity” subset of receptor population
in the imaging experiments, while antagonists bind to all
receptors disregarding “affinity states” [9].
Though the existence of a separate “high-affinity state”
subpopulation of D2/3R in the brain is still not conclusively
demonstrated in vivo [10], radiolabeled D2/3R agonists in-
deed turned out to be more sensitive than the antagonist
[11C]raclopride to amphetamine-induced release of dopa-
mine (itself also an agonist) in rodents, cats, non-human
primates, and humans [11–17]. Alteration of the relative
abundance of “high-affinity state” D2/3Rs (D2/3R-high), de-
tected by in vitro methods, is implied in dopamine super-
sensitivity, a state relevant to psychosis, Parkinsonism, and
drug addiction [18]. Changes in this in vitro-based param-
eter are likely to be translated into effects observable
in vivo, so agonist tracers might provide new insights for
the research into, and (early) diagnosis of, these common
neuropsychiatric disorders.
Numerous scaffolds have been investigated in the de-
velopment of D2/3R agonist PET tracers [19], but repre-
sentatives of only two classes, namely the apomorphines
[11C](−)NPA and [11C]MNPA and the naphtoxazine
[11C](+)PHNO, have hitherto been used in human PET
studies. These tracers can only be used in hospitals
with an on-site cyclotron due to the short half-life
of carbon-11. Fluorine-18-labeled tracers (half-life of
109.8 min) have greater potential of widespread ap-
plication in the clinic and are also more suitable for
long-duration experiments in the research set-up.
[18F]5-OH-FPPAT, an aminotetraline tracer, showed
promising results in rats and monkeys [20], but no
evaluation in humans has been published so far. A
[18F]fluorinated analog of [11C](+)PHNO failed to
demonstrate D2/3R-specific binding in rats [21], while the
recently described [18F]MCL-524, structurally related
to [11C]MNPA, showed very promising results in non-
human primates [22].
We aimed to increase the availability of fluorine-18-
labeled D2/3R agonist tracers for PET. For this purpose,
we selected the 2-aminomethylchroman-7-ol (AMC)
scaffold. Structure-activity relationships of this class ofhigh-affinity D2R-agonists were previously investigated
by Mewshaw and co-workers [23].
Recently, we have described the preparation of two [18F]-




compounds, when tested in their non-radioactive [19F]-
form, showed nearly full agonism at the long isoform of
human D2R and low-nanomolar affinities towards the
high-affinity state of these receptors: on average 5.6
and 6.7 nM for FBu-AMC13 and FEt-AMC15, respect-
ively. The affinities of these two compounds towards
human D2R and D3R were comparable to each other,
with no detectable preference for any of the two receptor
subtypes [24]. Both [18F]FBu-AMC13 and [18F]FEt-AMC15
also demonstrated specific binding to the D2/3R-high in rat
striata. We wanted to further evaluate these radioligands
in vivo and optimize their brain penetration and non-
specific binding by adjusting their lipophilicity. We rea-
soned that the latter goal could be achieved by varying
the length of the [18F]fluoroalkyl chain in the structures
of the tracers, because these chains are situated outside
the main pharmacophore of the AMCs [24], so short-
ening or elongating them will likely have no influence
on the affinity of the resulting ligands towards D2/3R.
This study reports on the synthesis of [18F]-labeled
AMC13 and AMC15 homologues with varied alkyl chain




Reagents, chemicals, materials, and solvents were ob-
tained from commercial sources and were used as re-
ceived: Biosolve, Merck for solvents, Cambridge Isotope
Laboratories for deuterated solvents, and Aldrich, Acros,
ABCR, Merck, and Fluka for chemicals, materials, and
reagents. All solvents were of analytical grade quality.
1H-NMR and 13C-NMR spectra were recorded on Var-
ian MR (300 or 400 MHz for 1H-NMR, 100 MHz for
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Chemical shifts are reported in ppm, applying deuterated
chloroform (CDCl3) or other deuterated solvents as in-
ternal reference. Abbreviations used for splitting pat-
terns are s = singlet, t = triplet, q = quartet, m =multiplet,
and dd = double doublet.
LC-ESI-MS/MS analyses were performed on a Shimadzu
LC-20AD series LC coupled to an API3000 mass spectrom-
eter (Applied Biosystems/MDS SCIEX, Toronto, Canada), a
triple quadrupole mass spectrometer supplied with an at-
mospheric pressure ionization source, and an ion-spray
interface. Analyses were executed at 298 K using an Alltech
Alltima C18 5 μ 150 × 2.1 mm column using an injection
volume of 10 μL, a flow rate of 0.4 mL/min, and a gradient
of MeCN/propan-2-ol in H2O (from 5 to 95 % organic
component, where both MeCN/propan-2-ol and H2O con-
tain 0.1 % formic acid). MS/MS analysis was performed in
the multiple reaction monitoring mode.
Analytical thin layer chromatography (TLC) was per-
formed on Kieselgel F-254 precoated silica plates. Normal-
phase column chromatography was carried out on regular
silica gel 60 (0.040–0.063, Merck).
1,2-Ethanediol ditosylate, 1,3-propanediol ditosylate, 1,4-
butanediol ditosylate, 2-fluoroethyl tosylate, 3-fluoropropyl
tosylate, and 4-fluorobutyl tosylate were prepared according
to procedures described in the literature [24, 25]. Analytical
data (1H-NMR, 13C-NMR) were according to expectations.
The preparation and characterization of phenol precur-
sors for 18F-fluoroalkylation, (R) N-[7-(methoxymethoxy)-
chroman-2-yl]methyl 4-hydroxybenzyl amine, and (R)
1-(4-hydroxyphenyl)-4-(4-(7-hydroxychroman-2-yl)-3-aza-
butyl)-piperazine were described earlier by van Wieringen
et al. [24].
[19F]-references for FBu-AMC13 and FEt-AMC15
were prepared and characterized as described previously
by van Wieringen et al. [24]. Of the new homologous li-
gands, [19F]-reference was only prepared for FEt-AMC13,
the homologue that showed the most promising results
in vivo. Given the use of the very similar radiolabel-
ing methods for all ligands, and the close structural
relatedness of the new homologues to the originally
developed FBu-AMC13 and FEt-AMC15, we decided
not to prepare [19F]-references for other homologues.
(R)-2-[(4-(4-Fluoroethoxy)benzylamino)methyl]chroman-7-ol
([19F]-reference of FEt-AMC13)
A solution of (R) N-[7-(methoxymethoxy)chroman-2-
yl]methyl 4-hydroxybenzyl amine (28.4 mg, 0.11 mmol)
in 1.5 ml dry DMF and 5 mg NaH were stirred in an oil
bath at 80 °C. To this mixture 2-fluoroethyl tosylate
(22.8 mg, 0.11 mmol) dissolved in 1.2 ml dry DMF was
added in three portions of 0.4 ml over the period of
1 hour. The mixture was stirred at 80 °C for 24 h. After
that, the reaction mixture was cooled down and N2 wasbubbled through the solution to create an inert atmos-
phere. Then, 2 mL of 4 M HCl solution in dioxane was
added to the mixture, and it was stirred for 5 h at room
temperature in the atmosphere of N2. N2 was further
bubbled through the solution to remove volatile reaction
products from the mixture. Thereafter, the reaction mix-
ture was diluted with 50 mL water and the pH was
brought to 8–8.5 by addition of a Na2CO3-solution. The
mixture was extracted by CH2Cl2 (3 × 10 mL), organic
extract was washed with water (3 × 10 mL), dried with
Na2SO4, and evaporated in vacuo. The residue was puri-
fied using silica column chromatography (ethyl acetate/
methanol/triethylamine 100/5/1), giving 8.5 mg of the
product (24% yield), as a slightly yellowish solid.
1H NMR (CD3OD/CDCl3): δ = 7.37 (d, 2H), 6.98 (d, 2H),
6.87 (d, 1H), 6.39 (dd, 1H), 6.21 (d, 1H), 4.83 (t, 1H), 4.71
(t, 1H), 4.29 (t, 1H), 4.22 (t, 1H), 4.12 (m, 1H), 4.01
(bs 2H), 3.01 (m, 2H), 2.9–2.5 (multiple signals, 2H),
2.05–1.65 (multiple signals, 2H). 13C NMR (CD3OD/
CDCl3): δ = 162.7, 160.0, 158.2, 134.5, 133.9, 133.0,
118.8, 116.6, 112.5, 107.0, 86.6, 84.8, 76.6, 71.3, 71.1,
55.6, 55.2, 35.7, 33.4, 29.5, 27.3.
Radiochemistry
[18F]-fluoride was produced in the Scanditronix MC-17F
cyclotron (GE Healthcare) and delivered from the target
into the hotcell with helium overpressure. Fig. 2 gives an
overview of the applied radiochemistry.
Synthetic procedures were performed manually. Radio-
chemical conversions and purities were determined by
radio-HPLC using beta-sensitive detectors and dose-
calibrators (Veenstra Instruments) and by radio-TLC
using Cyclone phosphor storage screens (multisensitive,
Packard) and OptiQuant software.
Preparation of [18F]fluoroalkyl tosylates
[18F]-Fluoride in enriched H2
18O water was adsorbed on
an activated anion-exchange column (QMA) and later
eluted into the reaction vial with 1–1.5 mL of 1.5 mg/mL
K2CO3, 5 mg/mL Kryptofix solution in 9:1 v/v mixture of
acetonitrile and water, respectively. After the elution of
QMA, acetonitrile and water were evaporated at 130 °C
under nitrogen flow. For further water removal, 1 mL an-
hydrous acetonitrile was added into the reaction vial and
evaporated. Then, 5 mg of alkyl ditosylate precursor
(ethyl, propyl, or butyl) in 1 mL anhydrous acetonitrile
was added into the vial, the vial was sealed, and reaction
was carried out for 4 min at 130 °C followed by cooling
5 min. To the cooled reaction mixture, 1 mL of water was
added, and the resulting mixture was loaded into the HPLC
loop. [18F]fluoroalkyl tosylates were purified by reverse-
phase HPLC using Alltima C18 5μ 250 × 10 mm column
eluted with acetonitrile/water at 5 mL/min. Acetonitrile
content in the mobile phase was 65 % for [18F]fluorobutyl
Fig. 2 Labeling routes for the homologous series of [18F]AMC13 and [18F]AMC15
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tosylate. Under these conditions, retention times of all thee
[18F]fluoroalkyl tosylates were in the range of 6–8 min. Col-
lected radioactive fraction was diluted two- to three-
fold with water and 4-[18F]fluoroalkyl tosylate was
adsorbed on tC18 light Sep-Pak cartridge. The cart-
ridge was rinsed with 5 mL pure water and dried for
5 min in strong nitrogen flow.
Preparation of [18F]FEt-AMC13, [18F]FPr-AMC13, and
[18F]FBu-AMC13
(R) N-[7-(Methoxymethoxy)chroman-2-yl]methyl 4-hydro-
xybenzyl amine (1, 0.6 mg) in 30 μL dry DMF and 2–3 mg
NaH were put into a V-vial. Thereafter, the corresponding
[18F]fluoroalkyltosylate was eluted into the vial from the
tC18 light Sep-Pak cartridge with 0.6–0.7 mL dry DMF.
The reaction vial was sealed and the alkylation reaction
to acquire compounds 3 were conducted for 10 min
at 120 °C. Then, 1 mL 0.4 N HCl was added into the
vial with a syringe and deprotection of the MOM-group
followed that also lasted 10 min at 120 °C. The product
was purified by reverse-phase HPLC using Alltima C18 5μ
250 × 10 mm column eluted with acetonitrile/10 mM
H3PO4 at 5 mL/min. Acetonitrile content in the mobile
phase was 30 % for [18F]FEt-AMC13 and 35 % for
[18F]FPr-AMC13 and [18F]FBu-AMC13. Retention times
were 10.6 min for [18F]FEt-AMC13, 9.2 min for [18F]FPr-
AMC13, and 10.8 min for [18F]FBu-AMC13. Collected
HPLC fraction was diluted with 2–3 volumes of water and
the radioactivity was adsorbed on Oasis HLB SPE cart-
ridge. The cartridge was rinsed with 5 mL pure water and
radioactivity was then eluted with 1–2 mL absolute etha-
nol. Typical recovery was 20–40 % for pure ethanol and
80–90 % for 100/1 v/v mixture of ethanol with acetic orortho-phosphoric acid; in synthesis runs for in vivo experi-
ments, only pure ethanol was used. After partial or
complete evaporation of ethanol in nitrogen flow (with or
without application of vacuum), the tracer was formulated
in physiological saline (ethanol content in the formulated
tracer was kept below 10 %).
Preparation of [18F]FEt-AMC15, [18F]FPr-AMC15, and
[18F]FBu-AMC15
The procedure described above for [18F]AMC13 homo-
logues was also used for the preparation of [18F]AMC15
homologues, with the following modifications:
Instead of (R) N-[7-(methoxymethoxy)chroman-2-yl]methyl
4-hydroxybenzyl amine (1), (R) 1-(4-hydroxyphenyl)-4-
(4-(7-hydroxychroman-2-yl)-3-azabutyl)-piperazine (2)
was used as the precursor. MOM-protected molecules
4 were the intermediates for the [18F]AMC15 homo-
logues (Fig. 2). At the end of the deprotection step, the
reaction mixture was diluted with 10 mL water, titrated
with 1 M NaOH to pH of 4–7 and then put through
the Oasis HLB SPE cartridge. Adsorbed activity was
then eluted from the cartridge with 1 mL acetonitrile/
DMF mixture (1/1 v/v). Eluate was further diluted with
water to a total volume of 1.5–2 mL, and the crude
product was purified by HPLC using Alltima C18 5μ
250 × 10 mm column. For [18F]FEt-AMC15 purifica-
tion, the column was eluted with a gradient of aceto-
nitrile in 10 mM acetate buffer with pH 4.0 at 5 mL/
min (45 % acetonitrile during the first 2 min, then a lin-
ear decrease from 45 % at 2 min to 30 % acetonitrile at
15 min). Retention time of [18F]FEt-AMC15 was
8.4 min. [18F]FPr-AMC15 and [18F]FBu-AMC15 purifi-
cation the column was eluted with 25 % acetonitrile in
10 mM H3PO4 at 5 mL/min. Retention times were
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[18F]FBu-AMC15.
Non-carrier-added [18F]FEt-AMC15 was found to de-
compose on the silica plate, so before TLC runs with
[18F]FEt-AMC15 and its longer-chain homologues (in-
cluding the analysis of plasma and tissue extracts), the
start positions of the lanes on the TLC plate were pre-
treated with AMC15 oxalate standard aqueous solution
(2 μg in 2 μL) to hamper the on-plate decomposition.
Characterization and identity confirmation of tracers
All tracers were characterized by analytical radio-HPLC and
radio-TLC. Conditions and results of the characterization
are presented in Additional file 1: Table S1.
The presence of the corresponding “carrier” (i.e., tracer
molecules that contain a [19F]-atom) in the formulated
tracer solutions was confirmed by high performance liquid
chromatography-electron spray tandem mass spectrom-
etry (LC-ESI-MS/MS) analysis with the monitoring of
fragmentation reactions of the tracer molecules. For all
radioligands, ion current peaks with expected M/z ratios
giving expected fragmentation products were observed
(Additional file 1: Table S2). The identity of [18F]FEt-
AMC13, [18F]FBu-AMC15, and [18F]FEt-AMC15 was also
confirmed by co-elution with reference products.
LogD measurement
LogD of the tracers was measured using the radioactivity
remaining on the HLB SPE cartridges after their elution
with ethanol during the tracer formulation procedure
(see above). The cartridge was dried with nitrogen for
5 min and eluted with at least 1.5 mL n-octanol. A 500
μL portion of octanol eluate was mixed with 500 μL of 1
M phosphate buffer (pH 7.4) and vigorously vortexed for
5 min. The mixture was then centrifuged at 17,000g for
10 min and 3 × 100 μL aliquots of organic and aqueous
phase were loaded into a gamma-counter for radioactiv-
ity measurement. To correct for possible presence of
radioactive impurities in the tracer, aliquots of organic
and aqueous phases were later analyzed by radio-TLC,
and the counts obtained from the gamma-counter were
corrected according to the percentage of impurities
found in aqueous and organic phases. LogD was calcu-
lated with the following formula:
LogD ¼ lg CPMorg  X
tracer
org
CPMaq  X traceraq
 !
;
where CPMorg is the mean radioactivity of the organic
aliquots, X tracerorg is the mean percentage of radioactivity
accounting for intact tracer in organic aliquots (as deter-
mined from radio-TLC), and CPMaq and X traceraq are the
corresponding values for the aqueous phase.For each tracer batch used for logD determination,
the experiment was performed in duplicate. LogD
values are means calculated from at least two inde-
pendent experiments.
In vitro autoradiography
In vitro autoradiography assay was performed as previ-
ously described [24]. Frozen brains of young (10–12 weeks
of age; 300–350 g body weight) male Sprague-Dawley rats
(Harlan, Netherlands) were cut at −12 °C into sagittal
slices 20 μm thick using a Leica microtome, and the slices
were thaw-mounted on Superfrost (70 × 22 mm, Fischer)
adhesive slides. Only slices containing both striatal and
cerebellar regions were used. The slides with slices
mounted them were allowed to dry, then put into storage
boxes with silica gel bags and stored at −80 °C.
On the day of the experiment (within 1 week from the
preparation of the slices), the slides were taken out of
storage and allowed to come to room temperature for
5–10 min. Then, 1–1.2 mL of incubation buffer (50 mM
Tris-HCl, 5 mM KCl, 2 mM CaCl2, 2 mM MgCl2,
120 mM NaCl, pH 7.4 25 °C) was applied per slide, and the
slides were pre-incubated for 15 min at room temperature.
The buffer was then removed, and the slides were placed
into staining jars containing radioligand solution (concen-
tration range of 0.1–10 nM) in the incubation buffer with
or without 10 μM raclopride (D2/3 antagonist) or 100 μM
guanosine-5'-triphosphate sodium salt (GTP, stimulator of
G-protein uncoupling from the receptors). After 35 min of
incubation at 37 °C, slides were washed once with ice-cold
incubation buffer (3.5 min) and dipped for 30 s into ice-
cold distilled water to remove buffer salts.
After drying the slides in a stream of room-temperature
air, they were exposed on phosphor storage screens for
6–10 h. The storage screens were read by Cyclone
Storage Phosphor System (Packard Instruments Co.).
Quantification of plate readings was done with OptiQuant
software (version 3.00, Packard Instruments Co.).
MicroPET study in rats
Three radioligands were evaluated in vivo: the originally
developed [18F]FBu-AMC13 and [18F]FEt-AMC15, and
[18F]FEt-AMC13, the homologue that showed the best
results in the in vitro autoradiography experiments (see
“Results” section).
Animal experiments were performed by licensed in-
vestigators in compliance with the Law on Animal
Experiments of The Netherlands. The protocol was
approved by the Committee on Animal Ethics of the
University of Groningen. Young male (10–12 weeks
of age, 300–350 g body weight) Sprague-Dawley rats
(Harlan, the Netherlands) were used for all experiments.
The rats were maintained at a 12-h light/12-h dark regime
and were fed standard laboratory chow ad libitum.
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treated, at random, with physiological saline (controls) or
raclopride tartrate (1 mg/kg calculated per raclopride base,
equivalent to 2.9 μmol/kg). Saline and raclopride were ad-
ministered intravenously (1 mL/kg injected volume).
An additional group of saline pre-treated rats, injected
with [11C]raclopride, served as positive controls for D2/3R-
specific brain uptake.
Two rats were scanned simultaneously. Before all ma-
nipulations, animals were anesthetized with a mixture of
isoflurane/air (inhalation anesthesia, 5 % ratio during in-
duction, 2 % at maintenance). Cannulae were placed into
the rats’ left femoral arteries and veins; the operation
took 45–50 min. The rats were positioned supine inside
the camera (Focus 220 microPET, Siemens-Concorde),
one above the other with their heads in the camera’s field
of view. A 515-s transmission scan with a Co-57 point
source was performed. Tracer was injected through the
venous cannula as a slow bolus (1 mL volume, 60 s long)
using an infusion pump. The second (upper) animal was
injected 16 min after the first (lower). Injected activities
and doses are given in Table 1.
PET acquisition was started during the injection of
radioactivity in the first rat. A 106-min long (76 min
long in the case of [11C]raclopride) list-mode acquisition
protocol was used for the scan.
Throughout the scan, arterial blood samples (15–19
samples; 0.10–0.15 mL each) were withdrawn from each
rat through the arterial cannula. Time intervals between
samples gradually increased from 5–10 s right after in-
jection to 30 min at the end of the scan. From each sam-
ple, 25 μL aliquots of whole blood were withdrawn. The
rest was centrifuged at 3500 g for 5 min; 25 μL super-
natant (plasma) aliquots were withdrawn and deprotei-
nated with 75 μL of ice-cold acetonitrile. From the
resulting 100 μL, 2–8 μL portions (i.e., 2–8 % of volume)
were taken for thin layer chromatography analysis
(radio-TLC) to assess radiometabolite content.
The radioactivity of the plasma and whole blood sam-
ples was measured using a well-type gamma-counter
(LKB-1282-Compugamma, LKB Wallac).
Radio-TLC was performed on silica plates. Samples of
the formulated tracers (diluted) were run along with
deproteinated plasma samples to confirm the identity ofTable 1 Injection data for the PET study
Tracer Injected activity, MBq/rat Injected dose, nmol/kg Rats
[18F]FEt-AMC13 9.4 ± 1.2 0.55 ± 0.14 4/4
[18F]FBu-AMC13 20.8 ± 10.6 0.45 ± 0.26, 10.4, 11.0a 3/3
[18F]FEt-AMC15 26.6 ± 15.2 1.06 ± 0.65 3/3
[11C]raclopride 16.9 ± 5.3 1.26 ± 0.16 4 (sal
One rat in the saline-treated group and one rat in the raclopride-treated group wer
measures (time-activity curves, uptake ratios) obtained from these animals were ve
results were not omitted or separated, but combined with the rest of the datathe parent compound in plasma. Eluent systems used
and TLC Rf values recorded are presented in Additional
file 1: Table S1.
After the end of the PET scans (i.e., 98 ± 8 min after
tracer injection), anesthetized animals were sacrificed by
heart extirpation and dissected. Samples of brain and per-
ipheral tissues were taken. All samples were weighed, and
their radioactivity was measured in a gamma-counter.
MicroPET image reconstruction and data analysis
List-mode data from the 106-min-long and 76-min-long
scans were reframed into, respectively, 90-min-long and
60-min-long dynamic sequences of 6 × 10, 4 × 30, 2 × 60,
1 × 120, 1 × 180, 4 × 300, 3 × 600, and (for 90-min-long
scans) 2 × 900 s frames. The data were reconstructed per
time frame using an iterative reconstruction algorithm
(attenuation-weighted 2-dimensional ordered-subset ex-
pectation maximization, provided by Siemens; 4 iterations,
16 subsets; zoom factor 2). Datasets were fully corrected
for random coincidences, scatter, and attenuation. Data
from the transmission scan were used for attenuation cor-
rection. The final datasets consisted of 95 slices, with a
slice thickness of 0.8 mm and an in-plane image matrix
size of 128 × 128 and pixel size of 0.47 × 0.47 mm.
Reconstructed images were analyzed with Inveon 2.0
software (Siemens Medical Solutions, USA, Inc). Regions
of interest (ROIs) were drawn manually on a T2-weighted
MRI template of rat brain around the striatum, brainstem,
cortex, hippocampus, hypothalamus, thalamus, olfactory
bulbs, and cerebellum around the whole brain and around
the pituitary gland. The MRI template was co-registered
with the PET scan by image fusion. The time-activity
curves (TAC) per ROI were determined in Bq/cm3 units
and converted into standardized uptake values (SUVs).
Kinetic analysis is described using the nomenclature
proposed by Innis et al. [26]. ROI TACs of [18F]FEt-
AMC13 were analyzed with one-tissue and two-tissue
compartmental models of reversible binding (1TCM and
2TCM, respectively) to obtain individual rate constants.
From these, the regional distribution volumes (VT) were
calculated and compared to those obtained with Logan
graphical analysis. Binding potentials (BPND) were calcu-
lated from the distribution ratios as VT (target) /VT (cere-




ine only) 36 ± 3
e injected, respectively, with 10.4 and 11.0 nmol/kg tracer. As all outcome
ry close to the results from other animals in the corresponding groups, these
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region.
Metabolite-corrected plasma-derived arterial input
function and whole blood time-activity curve were used
for Logan, 1TCM, and 2TCM analyses. Fractional cere-
bral blood volume was set to 3.6 % [27]. For one rat in
the raclopride-treated group, no input curves could be
obtained; therefore, its PET data were only analyzed with
SRTM.
Ex vivo autoradiography study in rats
To further assess the specific binding of [18F]FEt-
AMC13 to the striatal D2/3R, two groups of rats were
anesthetized, pre-treated with saline (n = 3) or raclopride
(n = 3), and 26 ± 3 min later injected with a bolus of
[18F]FEt-AMC13 (4.2 ± 1.4 MBq, 0.14 ± 0.04 nmol/kg)
into the penile vein. Rats were sacrificed by heart extir-
pation 35 min later. Brains were quickly extracted and
separated into two halves along the sagittal symmetry
plane or along the coronal plane spanning the thalamus.
One half of the brain (rostral or randomly taken
left/right) was quickly frozen over liquid nitrogen and
prepared for cutting on the microtome in the same
manner as brains used for in vitro autoradiography
[24]. Slices 40 μm thick were cut, mounted on Super-
frost glass slides, permitted to dry, and then directly
applied to the phosphor storage screens.
Another half of the brain was homogenized in 3 mL of
ice-cold acetonitrile using Heidolph IDAX600 homogenizer
at maximum speed. Homogenate was centrifuged at 3500g
for 5 min, and the supernatant (containing >95 % total
radioactivity) was analyzed by radio-TLC in the same way
as described above for the plasma.
D2/3R-specific binding quantification
Degree of D2/3R-specific binding of the tracers was char-
acterized by BPND (as given above) or the specific bind-
ing ratio (SBR) given as target region activity/cerebellar
activity - 1. Both were calculated under control condi-
tions and in response to the raclopride challenge.
Statistics
All data are presented as means ± standard deviations.
Comparison of means was done using 2-sided unpaired
Welch t test. p values below 0.05 were considered signifi-
cant. No multiple comparison corrections were performed.
Results
Preparation of radioligands
The labeling scheme used for the preparation of the
tracers is given in Fig. 2. Decay-corrected yields, radio-
chemical purities, specific activities, and logD values of
the prepared tracers are listed in Table 2. Radio-HPLC
and radio-TLC characterization data of the preparedtracers can be found in Additional file 1: Table S1. LC-
ESI-MS/MS characterization data of the [19F]-carrier
compounds in the decayed samples of purified tracers
are described in Additional file 1: Table S2.
For both [18F]AMC13 and [18F]AMC15 homologues,
reverse-phase radio-HPLC retention times, normal-phase
TLC retention factors, and logD values increased with the
length of the [18F]fluoroalkyl chain.
In vitro autoradiography
All [18F]fluoroethyl and [18F]fluoropropyl compounds
showed preferential uptake in the D2/3R-rich striatum
(Fig. 3). [18F]FEt-AMC13 had the highest striatal SBR,
followed by [18F]FPr-AMC13 and [18F]FEt-AMC15 (Table 3).
[18F]FBu-AMC13 only showed discernible specific binding
at the lowest concentration tested.
In the presence of 10 μM of raclopride, SBR values of
all AMC13 homologues decreased by 79–88 %, and
those of all AMC15 homologues by 60–64 % compared
to control conditions. GTP decreased the SBR values to
the same extent, implying that the striatal binding of all
tracers was predominantly to the high-affinity subset of
the D2/3Rs (Table 3).
In vivo and ex vivo brain uptake of the tracers under
control conditions
[18F]FEt-AMC13 and [18F]FBu-AMC13 showed good
blood-brain barrier (BBB) penetration (Fig. 4). Brain up-
take peaked at 0.7 % injected dose (ID) and 0.9 % ID, re-
spectively, 3 min after radiotracer injection.
For both tracers, the brain region with the lowest
uptake was the cerebellum. [18F]FBu-AMC13 had the
highest uptake in the brainstem, followed by the stri-
atum; striatum-to-cerebellum uptake ratio peaked at
1.41 ± 0.08 (Additional file 1: Figure S1. [18F]FEt-
AMC13 and [11C]raclopride had the highest uptake in
the striatum (Fig. 5). Striatum-to-cerebellum uptake
ratio of [18F]FEt-AMC13 peaked 45 min post-injection at
2.08 ± 0.25 (Fig. 5b); the same ratio measured by ex vivo
autoradiography was 2.81 ± 0.29 (35 min post-injection).
The striatum-to-cerebellum ratio of [11C]raclopride was
7.45 ± 1.60 (45 min post-injection; Fig. 5d).
[18F]FEt-AMC15 essentially did not penetrate the BBB.
Its in vivo brain uptake peaked at 0.2 % ID 3 min post-
injection and fell to 0.04 % ID 60 min post-injection.
Ex vivo measurements of the uptake of the tracers in
the brain and peripheral tissues performed after the PET
scan are given, respectively, in Table 4 and Additional
file 1: Table S3.
Tracer metabolism
[18F]FEt-AMC13 and [18F]FBu-AMC13 were quickly
metabolized in the plasma, while [18F]FEt-AMC15 was
more stable (Fig. 6). Tracers were eliminated from the
Table 2 Synthetic and analytical data for [18F]AMC13 and [18F]AMC15 homologues
Compound Isolated radiochemical yield, % Radiochemical purity, % End-of-synthesis specific activity, GBq/μmol logD
[18F]FEt-AMC13 12 ± 6 >95 102 ± 30 1.67 ± 0.07
[18F]FPr-AMC13 7 ± 6 >95 29 ± 27 1.98 ± 0.08
[18F]FBu-AMC13 8 ± 7 93 ± 2 85 ± 83 2.50 ± 0.06
[18F]FEt-AMC15 5 ± 3 93 ± 2 25 ± 15 1.48 ± 0.002
[18F]FPr-AMC15 3 ± 1 93 ± 5 9 ± 7 2.39 ± 0.001
[18F]FBu-AMC15 6 ± 0.3 93 ± 6 10 ± 3 2.71 ± 0.07
Values are means ± SD of ≥3 determinations from ≥2 independent experiments
Shalgunov et al. EJNMMI Research  (2015) 5:41 Page 8 of 13plasma with half-lives of 3 to 12 min. Radiometabolites of
all tracers in the plasma and in the brain tissue extract
were considerably more hydrophilic than their corre-
sponding parent compounds, as they all had TLC Rf
values of 0, compared to Rf of 0.16–0.56 for the tracers
themselves (Additional file 1: Table S1). Intact [18F]FEt-
AMC13 constituted 92 % of radioactivity from brain tissue
extract 35 min post-injection (Additional file 1: Figure S2).
Uptake in the parietal bone was lower than in the
brain tissue for all [18F]AMC13 homologues (Table 4),
suggesting low levels of in vivo defluorination.
Kinetic modeling for [18F]FEt-AMC13
2TCM and SRTM fits of ROI TACs were consistently bet-
ter than 1TCM fits (Additional file 1: Figure S3) as
assessed by Akaike’s information criterion, but the esti-
mates of individual rate constants of 2TCM were highly
variable and often physiologically implausible (Additional










* lowest concentration tried
Striatum Hippocampus
Fig. 3 Representative in vitro autoradiography images of rat brain
slices for the assayed radioligands. Left column—slides incubated
with radioligand only. Middle column—radioligand and 10 μM
raclopride. Right column—radioligand and 100 μM GTPThe most robust ROI VT estimates were obtained from
the Logan analysis (Additional file 1: Table S5). Logan VT
values correlated better with 2TCM VT (r = 0.97) than with
1TCM VT values (r = 0.89; Additional file 1: Figure S4). No
robust BPND estimates could be obtained from the k3/k4
rate constant ratio of 2TCM (data not shown), but BPND
estimates calculated from 1TCM, 2TCM, and Logan VT
data and obtained by SRTM correlated well with each other
for all regions except the pituitary and olfactory bulbs
(Additional file 1: Figure S5).
The highest BPND values in control rats were found
in the striatum (1TCM 0.63 ± 0.08; 2TCM 0.56 ± 0.05,
Logan 0.52 ± 0.01; SRTM 0.51 ± 0.02).Blocking experiments
Pre-treatment with 1 mg/kg (2.9 μmol/kg) raclopride de-
creased peak PET-based striatal SBR of [18F]FEt-AMC13
by 17 % (from 1.08 ± 0.25 to 0.90 ± 0.11), though the SBR
change was not statistically significant (p = 0.25). Striatal
SBR based on after-scan biodistribution measurements
decreased by 31 % (from 1.07 ± 0.10 to 0.74 ± 0.27), but
was also not statistically significant (p = 0.17). Ex vivo
autoradiography-based SBR fell by 39 % (from 1.81 ± 0.29
to 1.06 ± 0.17), which was statistically significant (p < 0.01),
and the blocking of D2/3R specific striatal binding
was clearly visible on the autoradiography images
(Additional file 1: Figure S6).
Striatal BPND fell by 18–27 % (p < 0.05 for 2TCM, Logan
and SRTM; see Table 5 and Additional file 1: Table S6) de-
pending on the kinetic model used. Modified Lassen plot
analysis [28] estimated the raclopride-induced D2/3R occu-
pancy at 20–25 % (p < 0.05 for 1TCM and 2TCM), while
41–55 % of striatal VT and 11–26 % of cerebellar VT were
estimated to be potentially displaceable, i.e., represent
D2/3R specific binding (Additional file 1: Figure S7).
For [18F]FBu-AMC13 pre-treatment with raclopride,
decreased absolute uptake in all brain regions, and stri-
atum-to-cerebellum uptake ratios were higher in raclo-
pride-treated group than in the saline-treated group
(Additional file 1: Figure S1c).




Striatal SBRb (% change relative to control condition)
Control Raclopride GTP
[18F]FEt-AMC13 0.9 ± 0.7 (n = 3) 3.40 ± 1.25 0.63 ± 0.53 (−81%)* 0.66 ± 0.52 (−81%)*
[18F]FPr-AMC13 1.4 ± 1.6 (n = 3) 2.07 ± 1.06 0.41 ± 0.23 (−80%)* 0.42 ± 0.23 (−80%)*
[18F]FBu-AMC13c 0.2 (n = 1) 0.85 ± 0.23 0.10 ± 0.19 (−88%)* 0.20 ± 0.16 (−76%)*
4.5 ± 3.6 (n = 3) 0.19 ± 0.18 0.04 ± 0.22 (−79%) –
[18F]FEt-AMC15c 5.8 ± 1.6 (n = 4) 1.64 ± 1.04 0.65 ± 0.37 (−60%)* 0.67 ± 0.28 (−59%)*
[18F]FPr-AMC15 5.0 ± 7.2 (n = 3) 1.01 ± 0.46 0.39 ± 0.22 (−61%)* 0.37 ± 0.24 (−63%)*
[18F]FBu-AMC15 2.3 ± 1.8 (n = 3) 0.69 ± 0.30 0.25 ± 0.23 (−64%)* 0.23 ± 0.23 (−67%)*
*p < 0.05 relative to control values, 2-sided Welch test
aConcentrations are means ± SD from n independent experiments
bSpecific binding ratio (SBR) values are means ± SD from the total number of slides (3–28 per condition) assayed in all experiments
cPublished earlier [24]
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caused no detectable alterations of radioactivity distribu-
tion in the brain (data not shown).
Discussion
We have previously described the design, synthesis, and
in vitro evaluation of a series of high-affinity D2/3 agonists
based on the AMC scaffold. Two compounds from that
series, FBu-AMC13 and FEt-AMC15, were confirmed to
have high-affinity towards D2/3R and act as agonists at D2R
[24]. They were [18F]-labeled and showed favorable results
in the in vitro autoradiography experiments. In this study,
we have evaluated these compounds in vivo and further op-
timized their characteristics by shortening or lengthening
the [18F]fluoroalkyl chains in their structures. We did not
directly measure the affinities and intrinsic activities of the
shorter-chain homologues of FBu-AMC13 and longer-
chain homologues of FEt-AMC15 towards D2/3R, as-
suming that changing the fluoroalkyl chain would have
negligible influence on these parameters, because this
fluoroalkyl chain is situated outside the main AMC
pharmacophore [24].
Both raclopride and GTP decreased striatal SBRs of all
tracers significantly and to a similar extent, which was
consistent across the homologous series (Table 3). This
indicates that all our tracers specifically bind to striatalFig. 4 Representative PET images for three [18F]fluoroalkyl-AMC radioligand
post-injection till the end of scan. Harderian glands (on top) are maskeddopamine D2/3 receptors in their G-protein-coupled
“high-affinity state.” Tracers with a shorter alkyl chain
showed higher in vitro autoradiography-based striatal SBR
values (Et > Pr > Bu). These findings are in agreement with
our hypothesis that varying the [18F]fluoroalkyl chain
length would influence non-specific binding, but not the
D2/3R-affinity or agonism of the tracers.
In vivo, [18F]FEt-AMC15 showed very low levels of
BBB penetration, which may be the consequence of the
tracer’s low lipophilicity and/or may imply that it is a
substrate for one of the drug efflux pump proteins such
as P-glycoprotein. Meanwhile, [18F]FEt-AMC13, which is
the short-alkyl-chain homologue of [18F]FBu-AMC13,
showed greatly improved specific-to-non-specific binding
ratios compared to the “original” radioligand, while retain-
ing good brain penetration and favorable metabolic profile.
Our approach has proven to be a useful and relatively
simple tactic for the adjustment of the radioligands’ lipo-
philicity with the goal of optimizing their non-specific
binding and brain penetration.
The time-activity curves of [18F]FEt-AMC13 were
better approximated with the 2TCM model than with
1TCM model, and 2TCM-derived VT and BPND esti-
mates correlated better than 1TCM-derived VT and
BPND estimates with the same data obtained from Lo-
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Fig. 5 Uptake of [18F]FEt-AMC13 (a, b) and [11C]raclopride (c, d) in rat brain. a, c Region-of-interest time-activity curves of control rats. b, d
Striatum-to-cerebellum ratios in rats pre-treated with saline (SAL) and 1 mg/kg (2.9 μmol/kg) raclopride (RAC). Points represent group means,
error bars show standard deviations
Table 4 Ex vivo uptake of the evaluated tracers in brain regions and skull bones of rats
Tracer [18F]FEt-AMC13 [18F]FBu-AMC13 [18F]FEt-AMC15
Treatment Saline Raclopride Saline Raclopride Saline Raclopride
Region (n = 4) (n = 4) (n = 3) (n = 3) (n = 3) (n = 3)
Striatum 0.28 ± 0.03 (1) 0.23 ± 0.08 1.60 ± 0.33 (5) 1.21 ± 0.14 0.02 ± 0.02 0.03 ± 0.01
Hippocampus 0.22 ± 0.02 (2) 0.23 ± 0.08 1.50 ± 0.25 (6) 1.21 ± 0.06 0.03 ± 0.02 0.03 ± 0.01
Thalamus + hypothalamus 0.19 ± 0.003 (4) 0.19 ± 0.05 2.07 ± 0.70 (1) 1.07 ± 0.10 0.03 ± 0.01 0.03 ± 0.01
Cortex 0.18 ± 0.01 (5) 0.16 ± 0.04 1.50 ± 0.32 (7) 1.01 ± 0.11 0.03 ± 0.003 0.03 ± 0.01
Brainstem 0.18 ± 0.02 (6) 0.16 ± 0.04 1.97 ± 0.42 (2) 1.25 ± 0.14 0.03 ± 0.004 0.03 ± 0.01
Olfactory bulbs 0.17 ± 0.01 (7) 0.15 ± 0.04 1.85 ± 0.64 (3) 0.86 ± 0.09 0.03 ± 0.001 0.03 ± 0.02
Rest of brain 0.20 ± 0.02 (3) 0.18 ± 0.03 1.60 ± 0.25 (4) 1.10 ± 0.17 0.02 ± 0.02 0.03 ± 0.02
Cerebellum 0.13 ± 0.01 (8) 0.13 ± 0.02 1.11 ± 0.29 (8) 0.73 ± 0.08 0.03 ± 0.01 0.03 ± 0.01
Mean brain uptake 0.18 ± 0.01 0.16 ± 0.04 1.56 ± 0.33 1.03 ± 0.11 0.03 ± 0.01 0.03 ± 0.01
Pituitary 0.76 ± 0.08 0.59 ± 0.20 3.19 ± 0.29 2.72 ± 0.77 1.36 ± 0.30 1.08 ± 0.27
Parietal bone 0.10 ± 0.01 0.10 ± 0.01 0.61 ± 0.17 0.70 ± 0.18 0.09 ± 0.03 0.08 ± 0.03
Data are presented as means ± standard deviations of standard uptake values. The ranking of the uptake magnitude (highest to lowest) among brain regions
within the BBB is shown in parentheses (only for [18F]AMC13 homologues)














































Fig. 6 Metabolism and pharmacokinetics of [18F]FEt-AMC13, [18F]FBu-AMC13, and [18F]FEt-AMC15 in the plasma of living rats. a Percentage of intact
tracer in the total plasma radioactivity. b Concentration of intact tracer in the plasma (i.e., metabolite-corrected plasma input curves). Points represent
group means, error bars show standard deviations. Horizontal axes show time after tracer injection
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model did not always provide reliable estimates of the
individual rate constants of [18F]FEt-AMC13 uptake in
the brain. This may have been caused by the quality of in-
put data: insufficient counts or imprecise estimates of the
plasma input can make the optimization routine converge
at a local minimum. Fortunately, the estimates of VT and
BPND were more robust and consistent, so these were
used for the evaluation of [18F]FEt-AMC13.
Estimation of the magnitude of the D2/3R blockade in-
duced by 1 mg/kg (2.9 μmol/kg) raclopride in rats’ striata
in vivo performed with the use of different approaches pro-
duced consistent results: changes in striatal BPND and (PET
and autoradiography-derived) SBR were similar to the
modified Lassen plot-based estimate of D2/3R occupancy by






Striatum 0.56 ± 0.05 0.41 ± 0.05 (−2
Hippocampus 0.30 ± 0.07 0.26 ± 0.06 (−1
Thalamus 0.33 ± 0.02 0.30 ± 0.01 (−1
Hypothalamus 0.22 ± 0.03 0.18 ± 0.06 (−1
Cortex 0.13 ± 0.04 0.10 ± 0.02 (−2
Brainstem 0.22 ± 0.02 0.10 ± 0.02 (−5
Olfactory bulbs 0.08 ± 0.13 0.01 ± 0.04 (−8
Pituitary 0.36 ± 0.07 0.13 ± 0.04 (−2
Data are presented as means ± SD, n = 4 for the control group and n = 3 for the rac
the BPND values of the raclopride-treated group, percentage of change relative to t
*p < 0.05; **p < 0.01, 2-sided Welch testtreatment blocked 17–39 % of D2/3R-specific signal in the
striatum. Though a bolus dose injected in an in vivo experi-
ment cannot be directly compared with ligand concentra-
tion applied in an in vitro experiment, our in vivo findings
are also arguably consistent with our in vitro findings,
where a higher concentration of raclopride (10 μmol/L)
used in the in vitro autoradiography study induced a greater
decrease (81 %) in striatal SBR in rat brain slices compared
to control conditions.
Our in vivo findings, however, do not agree with the
published studies which reported >90 % displacement of
apparent D2/3R-specific striatal uptake of [
11C]MNPA
and [11C]PHNO in Sprague-Dawley rats with 1–2 mg/kg
(2.9–5.8 μmol/kg) raclopride [29–31]. Even a fivefold
lower dose (0.2 mg/kg, 0.58 μmol/kg) displaced over 80 %
of apparent D2/3R-specific [
11C](+)PHNO uptake [30]. It isregion in control and raclopride-treated rats
SRTM BPND
Control Raclopride
7%)* 0.51 ± 0.02 0.38 ± 0.05 (−26%)**
3%) 0.26 ± 0.04 0.23 ± 0.05 (−13%)
0%)* 0.28 ± 0.06 0.26 ± 0.02 (−7%)
9%) 0.21 ± 0.03 0.16 ± 0.04 (−23%)
7%) 0.11 ± 0.03 0.08 ± 0.02 (−24%)
3%)** 0.18 ± 0.04 0.07 ± 0.03 (−60%)**
8%) 0.10 ± 0.13 0.11 ± 0.05 (+10%)
3%) 0.71 ± 0.32 0.55 ± 0.53 (−22%)
lopride-treated group (except for the SRTM BPND values, where n = 4). Next to
he control group is shown
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AMC13 from the striatum by 1 mg/kg raclopride is lower
than what is reported for other D2/3R tracers in the litera-
ture. It is unlikely that we violated the so-called tracer con-
ditions because crude estimation of the D2/3R occupancy
by [18F]FEt-AMC13 itself using the approach described by
Skinbjerg et al. [32] produced the values of no more
than 3 % in all our experiments. It may be that the
signal-to-noise ratio in our data was insufficient, which
made it difficult to precisely estimate the contribution of
specific binding to total tracer binding in various ROIs.
The presence of specific binding of [18F]FEt-AMC13 to
sites other than D2/3R, which has a comparatively high
density in the striatum, may also be implied. We have pre-
viously demonstrated that FBu-AMC13, a longer-chain
homologue of FEt-AMC13, has low affinity towards D1
receptors (7 μM on average) [24], while (R)-2-[(benzylami-
no)methyl]chroman-7-ol and 2-[(4-hydroxybenzylamino)
methyl]chroman-7-ol, compounds structurally closely re-
lated to FEt-AMC13, were shown by Mewshaw and co-
workers to be selective for D2/3R against serotonin-1A and
adrenergic α1 receptors [23]. In the in vitro autoradiography
study, presence of 10 μmol/L raclopride decreased striatal
SBR of [18F]FEt-AMC13 by 81 %, which also does not sup-
port the hypothesis of the existence of significant non-D2/
3R-specific binding of [
18F]FEt-AMC13 in the striatum.
Still, a separate study of pharmacological selectivity of FEt-
AMC13, including direct determination of the affinities of
FEt-AMC13 towards high- and low-affinity states of D2/3R,
is necessary to clarify this issue.
Apart from the striatum, the olfactory bulbs and pitu-
itary gland are known to contain high densities of D2/
3R available to agonist radioligands [33]. However, no
blocking effect of raclopride could be observed in these
regions (Tables 4 and 5), and the relatively high tracer
uptake in the pituitary is more likely to be explained by
the pituitary being situated outside the BBB than by the
presence of D2/3R-specific binding of [
18F]FEt-AMC13
there.
A striatum-to-cerebellum ratio of 2.08 is on par with the
value of 2 reported in rats for [18F]5-OH-FPPAT [20] and
with the value of 1.97 obtained for our other separately
evaluated AMC derivative [18F]AMC20 [34]. However, the
striatal BPND values of 0.51–0.63 obtained for [
18F]FEt-
AMC13 are lower than the values of at least 0.8–1.0 re-
ported in rodents for existing [11C]-labeled D2/3 agonists
[19, 29, 31]. Non-specific binding of the tracer in the tissue
can slow down the association rate of the tracer-receptor
binding by leaving less free tracer in the tissue. The launch
of the canonical signaling cascade induced by agonist
binding eventually leads to the uncoupling of the G-
protein from the receptor and the relaxation of the
receptor into its low-affinity state [18, 35], which may
increase the effective dissociation rate of an agonisttracer from the receptors. To find out which factors
limit the signal-to-noise ratio of [18F]FEt-AMC13, a
more thorough study of its binding kinetics in a more
controlled environment (e.g., in vitro) is necessary.
Conclusions
We have evaluated two homologous series of agonist ra-
diopharmaceuticals based on the AMC scaffold that bind
with high affinity and selectivity to D2/3R in vitro. Varying
the length of the [18F]fluoroalkyl group allowed us to sig-
nificantly improve the specific-to-non-specific binding ra-
tio of one of our original structures. The resulting ligand,
[18F]FEt-AMC13, demonstrated specific binding to the
striatal D2/3R in vitro as well as in vivo. In vitro findings
also confirmed the tracer’s binding to the high-affinity
state of D2/3R. Further investigation of the binding charac-
teristics of FEt-AMC13 and optimization of its molecular
structure can lead to an improved [18F]-labeled radioli-
gand suitable for clinical D2/3R imaging by PET.
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